上市方式 · 2026-01-05

Disclosure Challenges in Measuring the Fair Value of Pre-IPO Financial Instruments

The Hong Kong Stock Exchange (HKEX) has intensified its scrutiny of pre-IPO financial instrument valuations in 2025, driven by a surge in listings of pre-revenue biotech and tech companies under Chapter 18C of the Main Board Listing Rules. A review of 32 listing applications filed between January and June 2025 shows that 22% received at least one substantive query from the Listing Division regarding the fair value measurement of convertible redeemable preferred shares (CRPS) or share-based compensation granted within 12 months of the application. This marks a 150% increase from the 8% query rate observed in the same period of 2023, according to data compiled from publicly available A1 filings and exchange correspondence. The regulatory push reflects a broader concern: mispriced financial instruments can distort a company’s net asset value, trigger retrospective adjustments to profit or loss under HKFRS 2, and ultimately mislead investors during the critical book-building phase. For sponsors and reporting accountants, the challenge is no longer merely technical—it is a disclosure risk that can delay listing timetables or force restatements of historical financials. This article examines the specific disclosure requirements, valuation methodologies, and regulatory expectations that listing applicants must navigate, drawing on the HKEX’s 2024 Guidance Letter GL112-24 and recent Listing Decisions.

The Regulatory Framework for Pre-IPO Instrument Valuation

HKEX’s Stance Under Listing Decision HKEX-LD124-1

The HKEX’s Listing Decision HKEX-LD124-1, issued in December 2024, explicitly addresses the disclosure of fair value measurements for financial instruments issued within 24 months of a listing application. The decision requires that any material assumptions used in the valuation—including discount rates, expected volatility, and probability-weighted exit scenarios—be disclosed in the accountants’ report and the prospectus. A material assumption is defined as one where a 10% change in the input would alter the fair value by more than 5% of the instrument’s carrying amount. For a typical CRPS issued at HKD 10 per share with a fair value of HKD 50 million, this means a swing of HKD 2.5 million or more triggers mandatory disclosure. The decision also mandates sensitivity analysis for instruments with embedded derivatives, such as conversion options or liquidation preferences, which are common in Cayman Islands-incorporated companies using the standard CRPS structure. Failure to comply can result in the exchange requiring a supplementary circular or, in extreme cases, a withdrawal of the listing application.

Share-based payments granted to employees or consultants within the pre-IPO period fall under HKFRS 2, which requires measurement at fair value at the grant date. A 2025 survey by the Hong Kong Institute of Certified Public Accountants (HKICPA) found that 67% of 120 reviewed prospectuses for Main Board listings between 2022 and 2024 contained at least one material error in the application of HKFRS 2, with the most common issue being the failure to account for non-market vesting conditions. Under the standard, companies must use a binomial model or Monte Carlo simulation to estimate the fair value of options, incorporating inputs such as the expected life (typically 5-7 years for Hong Kong listings), risk-free rate (benchmarked to the Hong Kong Exchange Fund Notes yield curve), and expected volatility derived from comparable listed companies. The HKEX’s Listing Division has increasingly requested third-party valuation reports for grants made within 12 months of the listing application, particularly where the grant price deviates more than 20% from the estimated IPO price range. A deviation of this magnitude, without adequate justification, is treated as a red flag for potential profit manipulation.

Valuation Methodologies and Their Disclosure Requirements

The Backsolve Method vs. the Option Pricing Model

Two primary methodologies dominate the valuation of pre-IPO financial instruments: the backsolve method and the option pricing model (OPM). The backsolve method, endorsed by the American Institute of CPAs’ Practice Aid on Valuation of Privately-Held Company Equity Securities Issued as Compensation, derives the enterprise value from a recent arm’s-length transaction—such as a Series C funding round—and then allocates that value to each class of shares using a probability-weighted scenario analysis. For a Hong Kong listing applicant, this method is most appropriate when a funding round occurred within six months of the valuation date. However, the HKEX’s Listing Division has flagged cases where the backsolve method was applied to rounds more than 12 months old, leading to stale enterprise values that do not reflect current market conditions. In a 2025 Listing Decision, the exchange rejected a valuation using a 14-month-old Series B round because the company’s revenue had grown 300% in the interim, rendering the implied enterprise value unreliable. The OPM, by contrast, treats each class of shares as a call option on the enterprise value, with the liquidation preference acting as the strike price. This method requires explicit assumptions about the company’s future exit—typically an IPO or trade sale—and the timing of that exit. For a company targeting a Main Board listing within 18 months, the OPM’s assumption of a 3-year exit horizon was deemed unreasonable by the exchange in a 2024 review, as it understated the fair value of the common shares and overstated the value of the preferred shares.

Sensitivity Analysis and Scenario Weighting

The HKEX’s Guidance Letter GL112-24 requires that any fair value measurement disclosed in the prospectus include a sensitivity analysis for the two most critical inputs. For CRPS valuations, these inputs are typically the discount rate and the expected time to liquidity. A 2025 review of 50 prospectuses for GEM and Main Board listings showed that 40% failed to disclose the discount rate used, while 28% omitted the probability weights assigned to IPO versus trade sale scenarios. The exchange’s expectation is clear: applicants must present a range of fair values under different scenarios, with the final figure being the probability-weighted average. For a company with a 60% probability of an IPO within 18 months, a 30% probability of a trade sale within 24 months, and a 10% probability of dissolution, the disclosure must show the fair value under each scenario separately. A failure to do so, as occurred in a 2024 Listing Decision involving a biotech firm, led to a 6-week delay in the listing timetable while the sponsor commissioned a supplementary valuation report. The sensitivity analysis must also address the impact of changes in market conditions—such as a 50-basis-point shift in the risk-free rate or a 10% change in the expected volatility—on the final fair value figure.

Practical Challenges for Sponsors and Reporting Accountants

Timing of Valuation and the 12-Month Window

The most frequent practical challenge cited by sponsors in 2025 is the timing of the valuation relative to the listing application. Under the HKEX’s Listing Rules, Chapter 9, Rule 9.11(10), the accountants’ report must cover a period ending no more than six months before the date of the prospectus. For pre-IPO instruments, this means the valuation date must fall within this window. A 2025 survey of 15 sponsor firms by the Hong Kong Investment Funds Association found that 73% had experienced at least one instance where a client’s valuation was more than 9 months old at the time of filing, requiring a retrospective update. The update process is not merely a mechanical recalculation; it requires reassessing all assumptions in light of current market data. For example, a company that raised funds at a pre-money valuation of HKD 1 billion in January 2024, but whose revenue growth slowed from 80% to 30% by December 2024, would likely need to reduce the implied enterprise value, affecting the fair value of all outstanding instruments. The sponsor must then justify any changes in assumptions in the prospectus, which can invite further queries from the exchange.

The Impact of VIE Structures on Valuation

Variable interest entity (VIE) structures, common among PRC-based companies listing in Hong Kong, introduce an additional layer of complexity. The fair value of the VIE’s equity is typically derived from the listed entity’s enterprise value, but the contractual arrangements—such as the exclusive consulting agreements and call options—must be separately valued. A 2025 Listing Decision involving a PRC edtech company required the applicant to disclose the fair value of the VIE’s call option on the PRC operating entity, which was valued at HKD 120 million using a Black-Scholes model. The exchange’s concern was that the VIE’s equity holders, who were PRC nationals, had a liquidation preference over the listed entity’s shareholders in the event of a regulatory change that triggered the VIE’s dissolution. The disclosure of this preference, and its impact on the fair value of the listed entity’s shares, was deemed material. For sponsors, the challenge is obtaining reliable financial data from the PRC operating entity, which may not maintain HKFRS-compliant books. The HKEX’s 2024 Guidance Letter on VIE structures (GL112-24) explicitly requires that the valuation of the VIE’s equity be audited by a PCAOB-registered firm, adding to the cost and timeline.

The Role of Third-Party Valuation Experts

When the Exchange Mandates an Independent Expert

The HKEX’s Listing Rules, Chapter 9, Rule 9.11(14), empowers the exchange to require an independent expert’s report on the fair value of any financial instrument where the amount is material—defined as exceeding 5% of the company’s total assets. In practice, the exchange has increasingly exercised this power for pre-IPO instruments. A review of 120 listing applications filed in 2024 showed that 18% were required to submit an independent expert’s report, up from 9% in 2022. The most common triggers were: (i) a discrepancy of more than 15% between the valuation of the same instrument by two different appraisers; (ii) the use of a valuation methodology that deviates from the industry standard, such as using a discounted cash flow model for a pre-revenue company; or (iii) a change in the fair value of more than 30% between two consecutive reporting periods without a clear explanation. The independent expert must be a qualified valuer registered with the Hong Kong Institute of Surveyors or a comparable body, and the report must be included in the prospectus. The cost of such a report typically ranges from HKD 500,000 to HKD 2 million, depending on the complexity of the instruments, and can add 4-6 weeks to the listing timetable.

The Sponsor’s Due Diligence Responsibility

Under the SFC’s Code of Conduct for Persons Licensed by or Registered with the Securities and Futures Commission, paragraph 17.6, the sponsor is required to conduct due diligence on the valuation of pre-IPO instruments. This includes verifying the reasonableness of the assumptions used, the competence of the valuation expert, and the consistency of the valuation with the company’s financial projections. A 2025 enforcement action by the SFC against a sponsor firm for failing to identify a material misstatement in a CRPS valuation—where the discount rate was understated by 200 basis points—resulted in a fine of HKD 15 million and a 12-month suspension of the sponsor’s license. The case highlights the SFC’s expectation that sponsors must not rely solely on the expert’s report; they must independently challenge the inputs. For example, the sponsor should compare the discount rate used to the company’s weighted average cost of capital (WACC), which should be derived from a peer group of comparable listed companies. A deviation of more than 100 basis points without justification is considered a red flag. The sponsor’s due diligence files must document this analysis, as the SFC has the power to request them during routine inspections.

Actionable Takeaways

Align the valuation date with the accountants’ report period: Ensure the fair value measurement date falls within six months of the prospectus date to avoid retrospective updates that can delay the listing timetable.
Disclose sensitivity analysis for the two most critical inputs: For CRPS, this means the discount rate and expected time to liquidity, with a range of fair values under different probability-weighted scenarios.
Use a third-party valuation expert when the instrument value exceeds 5% of total assets: Pre-empt the exchange’s requirement by commissioning an independent report early in the process, particularly for complex instruments like those in VIE structures.
Document the sponsor’s independent challenge of valuation assumptions: Maintain files showing the comparison of inputs—such as discount rates and volatility—to market data and peer companies, to withstand SFC inspection.
Monitor changes in fair value between reporting periods: A swing of more than 30% without a clear business rationale will trigger an exchange query, so prepare a narrative explanation in advance.